Kamau Therapeutics a company in the clinicalstage of gene correction has recently emerged from stealth mode following a strategic deal with Graphite Bio
BioGenCell a leader in the field of personalized cell therapy solutions is pleased to announce the commencement of its fifth Phase II clinical trial site in the United States at the University of Maryland Medical Center
EnGeneIC an innovative biopharmaceutical company leading the field of armed antibody therapeutics for oncology has achieved a significant milestone with the FDA granting FastTrack designation for its pancreatic cancer therapeutic
Ten Therapeutics a biotechnology company has unveiled a collaboration with Boehringer Ingelheim for multitarget drug discovery The partnership aims to discover innovative therapeutic molecules to address diseases
Mendus AB a biopharmaceutical company specializing in immunotherapies for tumor recurrence has recently disclosed a partnership with the Australasian Leukaemia Lymphoma Group
Osteal Therapeutics has received Breakthrough Therapy Designation from the US Food and Drug Administration for VTX an investigational drug therapy targeting periprosthetic joint infection in the hip and knee
Alpha Cognition Inc a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders is pleased to announce that the US Food and Drug Administration
Xilio Therapeutics Inc a clinicalstage biotechnology company discovering and developing tumoractivated immunooncology therapies for people living with cancer today announced the initiation of enrollment for its Phase clinical trial
Synaffix BV a Lonza company focused on commercializing its clinicalstage platform technology for the development of antibodydrug conjugates with bestinclass therapeutic index
Phathom Pharmaceuticals Inc a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases announced today the FDA
New York, USA
Glasgow , UK
Kate, Editorial Team at Pharma Focus Europe, leverages her extensive background in pharmaceutical communication to craft insightful and accessible content. With a passion for translating complex pharmaceutical concepts, Kate contributes to the team's mission of delivering up-to-date and impactful information to the global Pharmaceutical community.
Ryan Varghese is a researcher affiliated with the Department of Pharmaceutical Sciences, Philadelphia College of Pharmacy, and Philadelphia, USA. His work spans a spectrum of topics from artificial intelligence to cancer theranostics and drug delivery in Alzheimer's disease. His specialization lies in the drug delivery modalities in chronic diseases. He has curated several articles on the lacunae in the Government’s public policies while providing solutions for the same. His recent work included the proposal on drug repurposing and affordable hospitalization to mitigate the risk stemming from COVID-19 in India. His current line of work lies in the efficient diagnosis and treatment of various cancers.
Rushil Dalal is a researcher currently affiliated with the Ludwig-Maximilians-Universität München. With a formal education in Biotechnology, his current lines of work encompass the development of novel therapeutics for oncological malignancies. Previously, he was associated with the Tata Memorial Centre - Advanced Centre for Treatment, Research and Education in Cancer (TMC-ACTREC). During his tenure, he has contributed significantly to the Department of Clinical Pharmacology, with his research in oncogenomics, where he was on the quest to elucidate SNPs that amplified the occurrence of tobacco-related head and neck cancer.
Jainam Karsiya is a clinical pharmacist and medical affairs executive associated with RiverRoute Creative Group, India. His domain of work expands across the length and breadth of oncology, ranging from drug delivery and clinical therapeutics to precision oncology. He has prior experience in nanotechnology, theranostics, and health outcomes research. He has also contributed to the drafting of public policies in the healthcare sector.
Dileep Kumar is an associate professor in the Department of Pharmaceutical Chemistry at Poona College of Pharmacy. He is a pioneer in his field with his forte in the treatment and novel drug delivery in Cancer and Alzheimer’s disease, especially adamantyl analogs as GluN2B selective NMDA receptor agonists. He is also an awardee of the Junior Research Fellowship from the National Medicinal Plant Board (NMPB) New Delhi, a Senior Research Fellowship from the University Grants Commission (UGC), a Teaching Assistantship, and an Institute Post-Doctoral Fellowship from IIT (BHU) Varanasi. He is the Guest Editor of prestigious journals like Current Topics in Medicinal Chemistry, Current Drug Target, combinatorial chemistry, and Molecules.
Vidya Niranjan, Ph.D. is a leading scientist and academic researcher excelling in computational biology. She has worked extensively on genome analysis, drug discovery, tools and database development. With extensive research experience of over 20 years, she has published over 100 research articles. She has bagged research funding worth 40 million USD from various government agencies and pharmaceutical companies. She is currently working on project related to quantum computing and protein folding funded by the Ministry of Electronics and Information Technology (MEITy) is an executive agency of the Union Government of the Republic of India in collaboration with Amazon AWS.
Director, Business Development Operations, Spring Bio Solution
Vidya Niranjan, Ph.D. is a leading scientist and academic researcher excelling in computational biology. She has worked extensively on genome analysis, drug discovery, tools and database development. With extensive research experience of over 20 years, she has published over 100 research articles. She has bagged research funding worth 40 million USD from various government agencies and pharmaceutical companies
The intersection of healthcare and politics in the United States is a convoluted landscape with various stakeholders vying for influence One of the most powerful and controversial players in this arena is the pharmaceutical industry often referred to as Big Pharma
Clinical trials serve as the cornerstone of medical research propelling advancements and supplying substantiation for the safety and effectiveness of novel treatments Historically these trials have been led by investigators prioritizing compliance with regulations and scientific goals
With the rise in COVID cases at an alarming rate the need for vaccines and subsequent booster doses is greater than ever But this begs the question of the Magic Number of booster doses
Quantum computings fusion with biochemistry ushers a new era of scientific exploration offering breakthroughs in pharmaceuticals This article explores quantum mechanics role in protein folding challenging classical norms
Decentralized clinical trials DCTs leads with a premise to leverage technology to transform the traditional clinical trials model Incorporating digital tools telemedicine and realworld data
In this editorial we explore the remarkable potential of artificial intelligence AI and machine learning ML in revolutionizing the field of drug design
Miro GTPases control mitochondrial morphology calcium homeostasis and regulate mitochondrial distribution by mediating their attachment to the kinesin and dynein motor complex It is not clear however how Miro proteins spatially and temporally integrate their function as acute disruption of protein function has not been performed
Pfizer has discovered a new drug elranatamab for the treatment of people with Relapsed or Refractory Multiple Myeloma RRMM Elranatamab is a Bcell maturation antigen BCMACDtargeted bispecific antibody BsAb
Navigating the complex and dynamic gene therapy regulatory landscape has been a persistent challenge for developers and manufacturers
Antibody drug conjugates ADCs are innovative modalities to deliver chemotherapeutics to specifically targeted populations of cancer cells
Clinical trials form the backbone of pharmaceutical development acting as the proving ground where the safety and efficacy of novel medical interventions are thoroughly evaluated
A number of exciting innovations have begun to gain the attention of companies within the pharmaceutical sector Artificial intelligence AI
The global pharmaceutical industry is currently facing many wide ranging challenges including an aging population increased life expectancy a rise in chronic conditions reduced funding for treatments reduced numbers of clinical staff the ever increasing cost of drug development and raw materials and supply chain issues
EBR systems are more reliable and compliance than traditional paper documents log in measures